IP Library Granted Patent US 11,091,487
Granted Patent B2
US 11,091,487 · App. 16/509,388 · Granted Aug 17, 2021

Meropenem derivatives and uses thereof

Inventors: Winston Zapanta Ong (Stoneham, MA); Pawel Wojciech Nowak (Woodcliff Lake, NJ); Jinsoo Kim (Brighton, MA); Elizabeth M. Enlow (Waltham, MA); James Bourassa (Somerville, MA); Yen Cu (Cambridge, MA); Alexey Popov (Waltham, MA); Hongming Chen (Belmont, MA)
Assignee: Kala Pharmaceuticals, Inc.
C07D477/20A61K9/5015A61K9/5031A61K9/5123A61K9/5146A61K31/407A61K45/06C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,091,487
App. No.
16/509,388
Granted
Aug 17, 2021
Kind
B2
Abstract

The present invention provides novel derivative of β-lactam antibiotics, such as meropenem. The inventive compounds include compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. Also provided are particles (e.g., nanoparticles) and pharmaceutical compositions thereof that are mucus penetrating. The inventive particles and pharmaceutical compositions may be useful in delivering an inventive compound to the respiratory tract of a subject. The invention further provides methods of using and kits including the inventive compounds, particles thereof, and/or pharmaceutical compositions thereof for treating and/or preventing a pulmonary disease (e.g., a respiratory tract infection).

Claims (63)

1. A compound having the formula:

or a salt thereof,

wherein

is a single bond or null,

is a single or double bond,

R B is —C(═O)—N(Me) 2 , —CH 2 —NH—S(═O) 2 —NH 2 , ═NH,

R A is substituted aliphatic, unsubstituted aliphatic, substituted heteroaliphatic, unsubstituted heteroaliphatic, substituted carbocyclyl, unsubstituted carbocyclyl, substituted heterocyclyl, unsubstituted heterocyclyl, substituted aryl, or unsubstituted aryl,

R C is substituted carbocyclyl, unsubstituted carbocyclyl, substituted aryl, unsubstituted aryl, substituted heteroaryl, or unsubstituted heteroaryl, and

R F is hydrogen or methyl.

2. The compound of claim 1 , wherein R C is unsubstituted carbocyclyl, substituted aryl, or unsubstituted aryl.

3. The compound of claim 1 , wherein R C is unsubstituted carbocyclyl, aryl substituted with halogen, or unsubstituted aryl.

4. The compound of claim 1 , having the formula:

or a salt thereof,

wherein R C is

5. The compound of claim 1 , having the formula:

or a salt thereof,

wherein

R C is

6. The compound of claim 1 , having the formula:

or a salt thereof,

wherein

R C is

7. The compound of claim 1 , having the formula:

or a salt thereof,

wherein

R C is

8. The compound of claim 1 , having the formula:

or a salt thereof,

wherein

R C is

9. The compound of claim 1 , having the formula:

or a salt thereof,

wherein

R C is

10. A composition, comprising the compound of claim 1 .

11. A composition, comprising the compound of claim 2 .

12. A composition, comprising the compound of claim 3 .

13. A composition, comprising the compound of claim 4 .

14. A composition, comprising the compound of claim 5 .

15. A composition, comprising the compound of claim 6 .

16. A composition, comprising the compound of claim 7 .

17. A composition, comprising the compound of claim 8 .

18. A composition, comprising the compound of claim 9 .

19. A compound having the formula:

or a salt thereof,

wherein

is a single bond or null,

is a single or double bond,

R B is —C(═O)—N(Me) 2 , —CH 2 —NH—S(═O) 2 —NH 2 , ═NH,

R A is substituted aliphatic, unsubstituted aliphatic, substituted heteroaliphatic, unsubstituted heteroaliphatic, substituted carbocyclyl, unsubstituted carbocyclyl, substituted heterocyclyl, unsubstituted heterocyclyl, substituted aryl, or unsubstituted aryl,

R C is substituted carbocyclyl, unsubstituted carbocyclyl, substituted aryl, unsubstituted aryl, substituted heteroaryl, or unsubstituted heteroaryl, and

R F is hydrogen.

20. A composition, comprising the compound of claim 19 .

21. A compound having the formula:

or a salt thereof,

wherein

is a single bond or null,

is a single or double bond,

R B is —CH 2 —NH—S(═O) 2 —NH 2 , ═NH,

R A is substituted aliphatic, unsubstituted aliphatic, substituted heteroaliphatic, unsubstituted heteroaliphatic, substituted carbocyclyl, unsubstituted carbocyclyl, substituted heterocyclyl, unsubstituted heterocyclyl, substituted aryl, or unsubstituted aryl,

R C is substituted aliphatic, unsubstituted aliphatic, substituted carbocyclyl, unsubstituted carbocyclyl, substituted aryl, unsubstituted aryl, substituted heteroaryl, or unsubstituted heteroaryl, and

R F is hydrogen or methyl.

22. A composition, comprising the compound of claim 21 .

Assignments (3)
FIRST AMENDMENT TO IP SECURITY AGREEMENT Recorded Dec 22, 2022
From: KALA PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC
Reel/Frame 062205/0883 →
SECURITY INTEREST Recorded May 6, 2021
From: KALA PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC
Reel/Frame 056168/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2019
From: ONG, WINSTON ZAPANTA; NOWAK, PAWEL WOJCIECH; KIM, JINSOO; ENLOW, ELIZABETH M.; BOURASSA, JAMES; CU, YEN; POPOV, ALEXEY; CHEN, HONGMING
To: KALA PHARMACEUTICALS, INC.
Reel/Frame 050154/0978 →
Continuity (4)
Continuation 15650667 · Jul 14, 2017
Continuation 14777018
Provisional Application 61789335 · Mar 15, 2013
Related Publication 20200010470A1 · Jan 9, 2020